ImaginAb, Quibim Collaborate to Revolutionize Immune Status Diagnosis and Immunotherapy Prediction

ImaginAb Inc., a global biotechnology company developing the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT), and Quibim, a global company founded with the goal of turning imaging data into...

Laurus gets tentative USFDA Approval For Paediatric HIV drug

The US Food and Drug Administration (USFDA) granted tentative approval to Laurus Labs Ltd for the world's first oral dispersible film (ODF) Dolutegravir 5mg and 10mg for paediatric anti-retroviral (ARV) treatment of HIV/AIDS...

Pfizer Beats Profit Estimates On Demand For New Drugs, COVID Products

Pfizer Inc on beat analysts' estimates for first-quarter profit on strong demand for its newly acquired drugs and steady demand for its COVID products, sending its shares up nearly three per cent before the bell. The company has said it expects...

Acelyrin Biopharma Aims For A $1.5 billion Valuation In Its US IPO

Acelyrin Inc, a late-stage clinical biopharma company, announced on Monday that it intends to seek a valuation of up to $1.5 billion in its initial public offering in the United States, which comes at a time when new listings are testing...

USFDA Approves Injectable Drug Treatment For Schizophrenia In Adults

The US Food and Drug Administration (FDA) has approved Uzedy (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults.Teva Pharmaceuticals' Uzedy is the first FDA-approved subcutaneous, long-acting risperi...

Japan's Astellas Pharma Agrees To Acquire Iveric Bio For $5.9 billion

Astellas Pharma of Japan announced on Monday that it has agreed to buy Iveric Bio Inc of the United States for approximately $5.9 billion in its largest acquisition to date, giving it access to a variety of ophthalmology treatments....

Indian Vaccine Market To Be Worth Rs 252 Billion By 2025: Jitendra Singh

Union Minister Jitendra Singh said on Sunday that the Indian vaccine market is expected to reach Rs 252 billion by 2025, highlighting the country's progress in the pharmaceutical and biotechnology sectors. On Sunday, Singh, who is leading a...

Bionomics completes enrollment in the phase 2b ATTUNE trial of BNC210 in patients with post-traumatic stress disorder

Bionomics Limited, a clinical-stage biopharmaceutical company, announced that it has reached its target enrollment of approximately 200 participants in its multi-center phase 2b ATTUNE clinical trial evaluating BNC210 in Post-Traumatic Stress...

WHO Announces New Pandemic Preparedness Initiative

WHO has launched a new project to assist countries in better preparing for future pandemics. The initiative gives guidelines on integrated planning for reacting to any respiratory infection, such as influenza or coronaviruses...

Why India is a Hotspot for Biotech Startups?

India has a large pool of scientists and engineers and a strong base for research and development,giving biotech startups access to experienced talent.

© 2024 India Pharma Outlook. All Rights Reserved.